Roche Breast Cancer Medicine to Get Expedited FDA Review
This article is for subscribers only.
Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease progressing.
The decision is based on research showing the medicine, called inavolisib, could offer a more effective first treatment option for women with a particular breast cancer mutation.